
Loading, please wait...

Loading, please wait...

The phase 3 LAIS trial, conducted at 32 hospitals in China, assessed intravenous loberamisal, a small molecule targeting the PSD-95 pathway and the α2 GABA-A receptor, in adults with acute ischemic stroke (NIHSS 7–20) treated within 48 hours of symptom onset. Of 998 randomized patients, 997 were analysed: 502 received loberamisal 40 mg once daily for 10 days and 495 received placebo, in addition to standard care. Full functional outcome (mRS 0–1) at 90 days was achieved by 69.7% of patients receiving loberamisal versus 56.3% receiving placebo (RR 1.24, 95% CI 1.12–1.36; risk difference 13.28%). Adverse events (87.8% vs 88.7%), serious adverse events (8.6% vs 10.7%) and all-cause mortality (1.2% vs 2.0%) were similar between groups. The authors state that further studies are needed to validate these findings and to determine whether the benefit extends to a broader stroke population.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The phase 3 LAIS trial, conducted at 32 hospitals in China, assessed intravenous loberamisal, a small molecule targeting the PSD-95 pathway and the α2 GABA-A receptor, in adults with acute ischemic stroke (NIHSS 7–20) treated within 48 hours of symptom onset. Of 998 randomized patients, 997 were analysed: 502 received loberamisal 40 mg once daily for 10 days and 495 received placebo, in addition to standard care. Full functional outcome (mRS 0–1) at 90 days was achieved by 69.7% of patients receiving loberamisal versus 56.3% receiving placebo (RR 1.24, 95% CI 1.12–1.36; risk difference 13.28%). Adverse events (87.8% vs 88.7%), serious adverse events (8.6% vs 10.7%) and all-cause mortality (1.2% vs 2.0%) were similar between groups. The authors state that further studies are needed to validate these findings and to determine whether the benefit extends to a broader stroke population.
Today

The 2025 Australian meningococcal surveillance report shows a 13% decline in invasive meningococcal disease notifications to 118 cases. Genogroup B accounted for 82.2% of typed infections, predominantly impacting infants and young adults, highlighting critical vaccination and rapid diagnostic imperatives.
Today

Doctors at AIIMS New Delhi have achieved a historic milestone by performing India's first open prenatal myelomeningocele repair on a 25-week unborn fetus. This landmark multidisciplinary procedure provides vital neuroprotective benefits, lowers hydrocephalus risks, and transforms maternal-fetal medicine nationwide.
Today

The ACE-PAS registry evaluated 21,612 patients fitted with the ASSURE wearable cardioverter defibrillator. The study demonstrated a 100% ventricular arrhythmia conversion rate, an inappropriate shock incidence of 0.0065 per patient-month, and high daily compliance of 23.1 hours, confirming real-world safety.
Today

A clinical overview of resveratrol supplementation in mitigating exercise-induced muscle damage. This narrative review explores physiological mechanisms, reductions in soreness markers like creatine kinase, dosage strategies, and bioavailability enhancements for sports medicine and nutrition practitioners.
Today

Childhood insulinoma is a rare cause of recurrent hyperinsulinemic hypoglycemia that often eludes early diagnosis. Advanced GLP-1 receptor-targeted PET/CT imaging using 68Ga-exendin-4 complements anatomic MRI to localize occult pancreatic lesions, facilitating focused, curative surgical enucleation.
Today